TARGETED RENAL THERAPY (TRT™)
Targeted Renal Therapy (TRT) is an approach pioneered by FlowMedica. It is the delivery of certain medications and other therapeutic agents directly to the kidneys via the renal arteries. TRT is an alternative to the standard delivery of systemic intravenous (IV) infusion to address kidney dysfunction related to a number of conditions, including cardiovascular, endovascular, and surgical procedures and diseases.
Systemic infusion often is associated with serious side effects such as hypotension. Clinicians have postulated that the amount of medication that reaches the kidneys via systemic infusion often does not attain therapeutic levels and therefore lead to treatment failure. As a result, physicians are now assessing the premise that TRT may maximize the benefit of medications because drugs can be delivered in therapeutic doses directly to the kidneys through the renal arteries. In addition, an investigator-sponsored study published in the American Journal of Cardiology suggests side effects will be minimized with TRT1 given that the kidneys eliminate a substantial amount of the drug infused directly into the renal arteries, limiting the amount of medication in circulation.
TRT can be used in numerous hospital settings including the Coronary Catheterization Laboratory, the Radiology Laboratory, the Surgical Suite, the Intensive Care Unit (ICU) and the Coronary Care Unit (CCU). Clinical use of FlowMedica's Benephit® CV Infusion System, Benephit PV Infusion System, and Benephit XT Infusion System may prove beneficial to interventional cardiologists, interventional radiologists, nephrologists, and interventionally skilled cardiothoracic and vascular surgeons.
Animation: Benephit Infusion System
This is an .wmv file. You may need Windows Media Player or QuickTime Player to view it.
Animation 5MB wmv file (1 min 58 sec duration)
|
